SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman caught up with Proactive London's Andrew Scott following the news they've agreed a deal with Dutch firm Winclove Probiotics to develop a food supplement to combat psoriasis.
The pair plan to carry out a human study on mild to moderate sufferers of the skin condition, which will take between 12 and 18 months ahead of commercialisation and launch of the probiotic.
Price: 39.1 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman talks to Proactive London about their wholly-owned subsidiary AxisBiotix Limited which is getting ready for their food supplement consumer study. The study, which will accept around 200 applicants, the participants will be asked to take a...
